2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Motor Activity
32
Breast Neoplasms
21
Neoplasms
17
Prostatic Neoplasms
11
Obesity
8
Sarcopenia
6
Colorectal Neoplasms
6
Pancreatic Neoplasms
5
Lung Neoplasms
5
Head and Neck Neoplasms
5
Polycystic Ovary Syndrome
4
Signs and Symptoms
3
Multiple Myeloma
3
Lymphedema
3
Inflammation
3
Fatigue
3
Diabetes Mellitus, Type 2
3
Colonic Neoplasms
3
Brain Neoplasms
3
Uterine Cervical Neoplasms
2
Pharyngeal Neoplasms
2
Overweight
2
Osteoporosis, Postmenopausal
2
Osteoporosis
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Laryngeal Neoplasms
2
Insulin Resistance
2
Hematopoietic and Lymphatic System Neoplasm
2
Interventions
Imatinib Mesylate
142
nilotinib
94
Cyclophosphamide
91
fludarabine phosphate
75
fludarabine
67
Dasatinib
63
Mycophenolic Acid
60
Whole-Body Irradiation
59
Tacrolimus
47
Busulfan
45
Cyclosporine
36
Peripheral Blood Stem Cell Transplantation
35
Cytarabine
35
Melphalan
30
bosutinib
27
ponatinib
26
Granulocyte Colony-Stimulating Factor
26
thymoglobulin
25
Thiotepa
25
Methotrexate
25
Filgrastim
25
asciminib
24
Antilymphocyte Serum
24
Stem Cell Transplantation
22
Sirolimus
17
Interferon-alpha
16
sargramostim
15
Cord Blood Stem Cell Transplantation
14
Clofarabine
13
Bone Marrow Transplantation
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
Resistance Training
×
Clear all
NCT07518940
2026-04-09
ENERGIA
University of Turin, Italy
Phase NA
Not yet recruiting
25 enrolled